1205P Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US

Autor: K. Sun, C.B. McGuiness, M.O. Jahanzeb, Pingkuan Zhang, M. Gorritz, D.R. Camidge, C-C. Chen, Y. Wu, H. Lin
Rok vydání: 2021
Předmět:
Zdroj: Annals of Oncology. 32:S960-S961
ISSN: 0923-7534
DOI: 10.1016/j.annonc.2021.08.1810
Databáze: OpenAIRE